Overview and Scope
Acute respiratory distress syndrome (ARDS) is a potentially fatal illness characterized by non-compliant, or stiff lungs and low oxygenation. It is an acute, diffuse and inflammatory form of lung injury that can occur in seriously ill patients. Acute respiratory distress syndrome (ARDS) treatment involves mechanical ventilation with low tidal volumes and positive end-expiratory pressure (PEEP) to support oxygenation and prevent lung injury.
Sizing and Forecast
The acute respiratory distress syndrome (ards) market size has grown rapidly in recent years. It will grow from $1.17 billion in 2023 to $1.29 billion in 2024 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to advancements in critical care medicine, aging population, pulmonary rehabilitation, multidisciplinary care teams.
The acute respiratory distress syndrome (ards) market size is expected to see rapid growth in the next few years. It will grow to $1.93 billion in 2028 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to global healthcare preparedness, vaccine development and infectious disease management, telemedicine and remote monitoring, patient-centered care models. Major trends in the forecast period include artificial lung devices, personalized ventilation strategies, lung protective ventilation, drug therapies for ards subtypes.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/acute-respiratory-distress-syndrome-ards-global-market-report
Segmentation & Regional Insights
The acute respiratory distress syndrome (ards) market covered in this report is segmented –
1) By Type: Diagnosis; Treatment
2) By Cause: COVID-19 Disease 2019 (COVID-19); Sepsis; Inhalation Of Harmful Substances; Severe Pneumonia; Other Causes
3) By Severity: Mild; Moderate; Severe
4) By End User: Hospitals; Clinics; Ambulatory Service Centers; Other End Users
North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2023. The regions covered in acute respiratory distress syndrome (ARDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13005&type=smp
Major Driver Impacting Market Growth
The growing prevalence of pneumonia is expected to propel the growth of the acute respiratory distress syndrome (ARDS) market going forward. Pneumonia is an infection that affects one or both lungs, causing the lungs’ air sacs, or alveoli, to fill up with fluid or pus. Pneumonia causes an inflammatory reaction in the lungs, increasing blood vessel permeability and fluid leakage into the alveoli. This fluid buildup interferes with the exchange of oxygen and carbon dioxide, causing respiratory discomfort. For instance, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2021, the number of deaths due to pneumonia in the United States was 41,309, with a mortality rate of 12.4 deaths per 100,000 population. Therefore, the growing prevalence of pneumonia drives the growth of the acute respiratory distress syndrome (ARDS) market.
Key Industry Players
Major players in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline PLC, Medtronic PLC, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, ResMed Inc., Smiths Medical Inc., Dräger Safety AG & Co. KGaA., Getinge AB, Mallinckrodt PLC, Masimo Corporation, United Therapeutics Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Zuventus Healthcare Ltd., Windtree Therapeutics Inc., Faron Pharmaceuticals Oy, AcelRx Pharmaceuticals Inc.
The acute respiratory distress syndrome (ards) market report table of contents includes:
1. Executive Summary
- Acute Respiratory Distress Syndrome (ARDS) Market Characteristics
- Acute Respiratory Distress Syndrome (ARDS) Market Trends And Strategies
- Acute Respiratory Distress Syndrome (ARDS) Market – Macro Economic Scenario
- Global Acute Respiratory Distress Syndrome (ARDS) Market Size and Growth
- Acute Respiratory Distress Syndrome (ARDS) Market Segmentation
- Acute Respiratory Distress Syndrome (ARDS) Market Regional And Country Analysis
………………
- Key Mergers And Acquisitions In The Acute Respiratory Distress Syndrome (ARDS) Market
- Acute Respiratory Distress Syndrome (ARDS) Market Future Outlook and Potential Analysis
- Appendix
List Of Tables :
Table 1: Global Historic Market Growth, 2018-2023, $ Billion
Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
Table 3: Global Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Table 4: Global Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Table 5: Global Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
…………………
Table 75: Johnson & Johnson Services Inc. Financial Performance
Table 76: Novartis AG Financial Performance
Table 77: GlaxoSmithKline plc Financial Performance
Table 78: Medtronic plc Financial Performance
Table 79: Boehringer Ingelheim International GmbH Financial Performance
Explore the trending research reports from TBRC:
https://topprnews.com/switchgear-monitoring-system-market-share/
https://goodprnews.com/metal-implants-and-medical-alloys-market-size/
Learn About Us:
The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
